tiprankstipranks
Chinook announces first patient enrolled in Phase 3 BEYOND study of BION-1301
PremiumThe FlyChinook announces first patient enrolled in Phase 3 BEYOND study of BION-1301
9M ago
Chinook Therapeutics presents data from CHK-336 Phase 1 trial
PremiumThe Fly
Chinook Therapeutics presents data from CHK-336 Phase 1 trial
10M ago
Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress
PremiumPress Releases
Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress
10M ago
Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress
PremiumPress ReleasesChinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress
11M ago
Lexicon has ‘only un-partnered asset’ in SGLT2i space, says Piper
PremiumThe Fly
Lexicon has ‘only un-partnered asset’ in SGLT2i space, says Piper
11M ago
Chinook Therapeutics downgraded to Neutral from Buy at Guggenheim
PremiumThe Fly
Chinook Therapeutics downgraded to Neutral from Buy at Guggenheim
11M ago
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress ReleasesChinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12M ago
Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress
PremiumPress Releases
Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress
12M ago
Chinook Therapeutics price target lowered to $35 from $43 at Guggenheim
PremiumThe Fly
Chinook Therapeutics price target lowered to $35 from $43 at Guggenheim
12M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100